NZSE:BLT

Stock Analysis Report

Executive Summary

BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand and internationally.

Snowflake

Fundamentals

Adequate balance sheet with questionable track record.

Share Price & News

How has BLIS Technologies's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-13.0%

BLT

-0.6%

NZ Pharmaceuticals

0.6%

NZ Market


1 Year Return

135.3%

BLT

-30.6%

NZ Pharmaceuticals

20.5%

NZ Market

Return vs Industry: BLT exceeded the NZ Pharmaceuticals industry which returned -30.6% over the past year.

Return vs Market: BLT exceeded the NZ Market which returned 20.5% over the past year.


Shareholder returns

BLTIndustryMarket
7 Day-13.0%-0.6%0.6%
30 Day14.3%1.5%3.0%
90 Day8.1%-3.4%2.2%
1 Year135.3%135.3%-30.4%-30.6%25.7%20.5%
3 Year-20.0%-20.0%-40.4%-41.0%55.8%35.4%
5 Year53.8%53.8%-15.3%-22.8%100.9%55.6%

Price Volatility Vs. Market

How volatile is BLIS Technologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BLIS Technologies undervalued compared to its fair value and its price relative to the market?

116.62x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BLT is poor value based on its PE Ratio (116.6x) compared to the Pharmaceuticals industry average (50x).

PE vs Market: BLT is poor value based on its PE Ratio (116.6x) compared to the NZ market (19.6x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLT is overvalued based on its PB Ratio (13x) compared to the XO Pharmaceuticals industry average (3.7x).


Next Steps

Future Growth

How is BLIS Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

70.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIS Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BLIS Technologies performed over the past 5 years?

29.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BLT has become profitable over the past 5 years, growing earnings by 29.9% per year.

Accelerating Growth: BLT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BLT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.1%).


Return on Equity

High ROE: BLT's Return on Equity (11.1%) is considered low.


Return on Assets

ROA vs Industry: BLT has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: BLT's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is BLIS Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: BLT's short term assets (NZ$4.0M) exceeds its short term liabilities (NZ$1.7M)

Long Term Liabilities: BLT's short term assets (4.0M) exceeds its long term liabilities (129.0K)


Debt to Equity History and Analysis

Debt Level: BLT's debt to equity ratio (24.2%) is considered satisfactory

Reducing Debt: Insufficient data to determine if BLT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: BLT's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: BLT's interest payments on its debt are well covered by EBIT (24.8x coverage).


Balance Sheet

Inventory Level: BLT has a low level of unsold assets or inventory.

Debt Coverage by Assets: BLT's debt is covered by short term assets (assets are 4.784070x debt).


Next Steps

Dividend

What is BLIS Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.9%markettop25%5.5%industryaverage2.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BLT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.


Next Steps

Management

What is the CEO of BLIS Technologies's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Brian Watson 0

3.7yrs

Tenure

0

Mr. Brian D. Watson has been Chief Executive Officer of BLIS Technologies Limited since February 15, 2016. Mr. Watson has strong sales and marketing credentials and experience. He serves as Group Manager o ...


Management Age and Tenure

3.1yrs

Average Tenure

Experienced Management: BLT's management team is considered experienced (3.1 years average tenure).


Board Age and Tenure

1.3yrs

Average Tenure

Experienced Board: BLT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Brian Watson

    Chief Executive Officer

    • Tenure: 3.7yrs
  • John Hale

    Chief Technology Officer

    • Tenure: 0yrs
  • Julie Curphey

    Chief Marketing Officer

    • Tenure: 3.1yrs
  • Richard Wingham

    Chief Financial Officer

    • Tenure: 1.9yrs

Board Members

  • Barry Richardson

    Independent Non-Executive Director

    • Tenure: 1.3yrs
    • Compensation: NZ$23.33k
  • Tony Offen

    Independent Chairman

    • Tenure: 2.2yrs
    • Compensation: NZ$66.00k
  • Alison Stewart (61yo)

    Independent Non-Executive Director

    • Tenure: 1.1yrs
    • Compensation: NZ$20.42k
  • Graeme Boyd

    Deputy Chairman

    • Tenure: 1.2yrs
    • Compensation: NZ$41.67k
  • Geoff Plunket

    Independent Non-Executive Director

    • Tenure: 1.4yrs
    • Compensation: NZ$38.75k

Company Information

BLIS Technologies Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BLIS Technologies Limited
  • Ticker: BLT
  • Exchange: NZSE
  • Founded: 2000
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NZ$43.198m
  • Shares outstanding: 1.11b
  • Website: https://www.blis.co.nz

Number of Employees


Location

  • BLIS Technologies Limited
  • 81 Glasgow Street
  • South Dunedin
  • Dunedin
  • 9012
  • New Zealand

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLTNZSE (New Zealand Stock Exchange)YesOrdinary SharesNZNZDAug 2001

Biography

BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand and internationally. The company markets two strains of probio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/23 10:31
End of Day Share Price2019/10/23 00:00
Earnings2019/03/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.